ADMA Biologics, Inc. (ADMA)
ADMA Price and Sentiment
ADMA Latest news
ADMA Biologics Inc (NASDAQ: ADMA) achieved Q3 sales of $20.7 million, + 101% Y/Y, beating the consensus of $18.72 million. The increase was favorably impacted by the continued commercial ramp-up of ADMA's intravenous immune globulin (IVIG) product portfolio and the sale of intermediate fractions.
ADMA Biologics, Inc. (ADMA) CEO Adam Grossman on Q3 2021 Results - Earnings Call Transcript
Adma Biologics (ADMA) delivered earnings and revenue surprises of 13.33% and 11.29%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
ADMA Biologics Reports Record Third Quarter 2021 Financial Results and Highlights Recent Progress and Accomplishments2021-11-10 16:01
Generated Record Total Revenues of $20.7 Million in the Third Quarter 2021, a 101% Increase Over Third Quarter 2020
ADMA Biologics (NASDAQ:ADMA) is set to give its latest quarterly earnings report on Wednesday, 2021-11-10. Here's what investors need to know before the announcement.
Conference Call Scheduled for November 10, 2021 at 4:30 p.m. ET Conference Call Scheduled for November 10, 2021 at 4:30 p.m. ET
ADMA has been trading in a downward trajectory over the past few years. ADMA's stock price has taken a beating from several equity offerings as the business continues to invest in the future.
Adma Biologics (ADMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ADMA Biologics Announces Closing of $57.5 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares2021-10-25 16:01
RAMSEY, N.J. and BOCA RATON, Fla., Oct. 25, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced the closing of its previously announced underwritten public offering of 50 million shares of its common stock at a public offering price of $1.00 per share, in addition to the exercise in full of the underwriters' option to purchase an additional 7.5 million shares of common stock. The gross proceeds from the exercise of the overallotment option were $7.5 million, bringing the total gross proceeds to ADMA from the offering to $57.5 million, before deducting underwriting discounts and commissions and other estimated offering expenses.
Penny stocks are seeing heightened momentum, which companies are you watching? The post Best Penny Stocks to Watch as The Market Turns Bullish appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.